<DOC>
	<DOCNO>NCT01757015</DOCNO>
	<brief_summary>This study evaluate add-on treatment inhale NVA237 ( 50 µg ) daily ( o.d . ) via single-dose dry-powder inhaler ( SDDPI ) improve lung function health status well tolerate compare placebo symptomatic COPD patient moderate severe airflow limitation already receive maintenance therapy inhale fixed-dose-combination salmeterol/fluticasone propionate ( 50/500 µg ) twice daily ( b.i.d . ) via multi-dose dry powder inhaler ( MDDPI ) .</brief_summary>
	<brief_title>Safety Efficacy NVA237 add-on Fixed Dose Combination LABA/ICS</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Current exsmokers smoke history least 10 pack year ( e.g. , 10 pack year = 1 pack/day × 10 year , ½ pack/day × 20 year , etc. ) . COPD ( Chronic Obstructive Pulmonary Disease ) patient moderate severe airflow limitation ( Spirometry classification : GOLD 2 3 ) Visit 2 : Postbronchodilator FEV1 ( Forced Expiratory Volume one second ) ≥30 % &lt; 60 % predict normal , , Postbronchodilator FEV1/forced vital capacity ( FVC ) &lt; 0.70 Patients maintenance treatment fixeddose combination inhale salmeterol fluticasone propionate ( 50/500 µg ) b.i.d . deliver via proprietary MDDPI ( multidose dry powder inhaler ) device least 30 day prior screen visit ( Visit 1 ) . Patients category Gold B D CAT ( COPD Assessment Test ) total score ≥10 screening ( Visit 1 ) randomization ( Visit 3 ) . Patients history least 1 moderate severe COPD exacerbation within previous year . Pregnant nursing ( lactate ) woman Women childbearing potential , unless use effective method contraception study Patients history long QT syndrome whose QTc measure runin ( Visit 2 ) ( Fridericia method ) prolong ( &gt; 450 m ) . ( These patient rescreened . ) Patients evidence ( upon visual inspection ) oropharyngeal candidiasis baseline without treatment . Patients achieve acceptable spirometry result runin ( Visit 2 ) accordance American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) criteria acceptability repeatability . Patients COPD exacerbation require treatment antibiotic oral corticosteroid hospitalization 6 week prior screen ( Visit 1 ) . Patients respiratory tract infection within 4 week prior screen ( Visit 1 ) . Patients require long term oxygen therapy prescribe &gt; 12 hour per day . Patients allergic rhinitis use H1 antagonist intranasal corticosteroid intermittently . ( Treatment stable dose regimen permit . ) Patients concomitant pulmonary disease ( e.g. , lung fibrosis , sarcoidosis , interstitial lung disease , pulmonary hypertension ) , clinically significant bronchiectasis , history pulmonary lobectomy , lung volume reduction surgery , lung transplantation . Patients active pulmonary tuberculosis , unless confirm imaging longer active . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Moderate severe airflow limitation</keyword>
	<keyword>GOLD spirometric classification 2 3</keyword>
	<keyword>GOLD group B D</keyword>
	<keyword>NVA237</keyword>
	<keyword>Salmeterol fluticasone propionate</keyword>
</DOC>